WAVEMAN · COMPANY

LLY · Eli Lilly & Co

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

LLY

Name: ELI LILLY & Co (LLY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ELI LILLY & Co

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000059478

CONGRESS · 4FORM 144 · 5☆ WATCH

INSIDER NET · 180D

-$34.6M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

2,613

13F, latest reported quarter

REVENUE GROWTH

+44.7%

XBRL, annual

NET MARGIN

31.7%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$34.6M over 180 days

-$18.8M over 90 days

below 93% of Pharma & Biotech

CONGRESS

4 members bought in the last year

more than 95% of Pharma & Biotech

FUNDS

2,613 funds added or opened last quarter

the highest in Pharma & Biotech

REVENUE

+44.7% year over year

more than 77% of Pharma & Biotech

MARGIN

31.7% net margin

more than 93% of Pharma & Biotech

BUYBACKS

$4.0B repurchased, FY to 2026-06-30

more than 99% of Pharma & Biotech

SHORT

1.0% of shares outstanding short · 3.9 days to cover · settled 2026-07-31

below 73% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$34.6M across 5 people in 180 days.

2,613 funds added or opened positions in the latest 13F quarter, of 4,628 holders.

4 members of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +58.8%

+58.8%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $34.6M sold by insiders over 180 days, 2,613 funds added last quarter, 4 Congress member(s) bought in 12 months, $737.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN ALNY ELF CITR MDGL DNA VRTX NUVL INSM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ELI LILLY & Co insiders sold a net $34.6M of stock across 1,147 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Jonsson Patrik

EVP & President, LLY Int'l

SELL

2026-08-17

6,500.0

$7.6M

Zakrowski Donald A

SVP, Finance, & CAO

SELL

2026-08-10

2,000.0

$2.4M

Hakim Anat

EVP, GC & Secretary

SELL

2026-08-07

5,000.0

$6.0M

Yuffa Ilya

EVP&Pres, LLY USA&Global Capab

SELL

2026-06-10

2,500.0

$2.9M

LILLY ENDOWMENT INC

—

SELL

2026-05-06

2,208.0

$2.2M

1,147 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 1,142 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

LILLY ENDOWMENT INC

90,376,978.0 sh

$108.4B

BlackRock, Inc.

67,540,400.0 sh

$81.0B

VANGUARD CAPITAL MANAGEMENT LLC

53,528,868.0 sh

$64.2B

PNC Financial Services Group, Inc.

51,322,720.0 sh

$61.6B

STATE STREET CORP

36,215,754.0 sh

$43.4B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Patrik Jonsson

FILED 2026-08-17

$7.6M

DONALD ZAKROWSKI

FILED 2026-08-10

$2.4M

Hakim Anat

FILED 2026-08-07

$11.9M

LILLY ENDOWMENT, INC.

FILED 2026-07-07

$372.0M

LILLY ENDOWMENT, INC.

FILED 2026-06-26

$343.9M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Pharmaceuticals Portfolio

$381.7M POSITION · AS OF 2026-02-28

25.2%

iShares U.S. Pharmaceuticals ETF

$210.7M POSITION · AS OF 2026-03-31

21.1%

Harbor Health Care ETF

$5.5M POSITION · AS OF 2026-04-30

20.1%

VanEck Pharmaceutical ETF

$240.5M POSITION · AS OF 2026-03-31

18.7%

PGIM Jennison Health Sciences Fund

$244.6M POSITION · AS OF 2026-02-27

16.8%

Roundhill GLP-1 & Weight Loss ETF

$8.3M POSITION · AS OF 2026-03-31

16.1%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Mr. Ricks

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$36.7M

$75.2M

$10.9M

+571%

+54%

2024

$29.2M

$80.6M

$6.1M

+378%

+23%

2023

$26.6M

$120.9M

$7.8M

+259%

+18%

2022

$21.4M

$64.1M

$5.8M

+123%

+25%

2021

$21.5M

$75.7M

$4.7M

+66%

+17%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$65.2B	$45.0B	$34.1B	$28.5B
NET INCOME	$20.6B	$10.6B	$5.2B	$6.2B
EPS (DILUTED)	22.95	11.71	5.80	6.90
OPERATING CASH FLOW	$16.8B	$8.8B	$4.2B	$7.6B
CASH	$7.3B	$3.3B	$2.8B	$2.1B
LONG-TERM DEBT	$40.9B	$28.5B	$18.3B	$14.7B
BUYBACKS	$4.1B	$2.5B	$750.0M	$1.5B
DIVIDENDS PAID	$5.4B	$4.7B	$4.1B	$3.5B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE